norucholic acid

Phase 3Small molecule

DDr. Falk Pharma GmbH

norucholic acid is one of 42 small molecule programs targeting Sclerosing Cholangitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Sclerosing CholangitisActive, not recruiting

Sclerosing CholangitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Sclerosing Cholangitis

#DrugCompanyPhaseTrials

Vancocin

HHikma Pharmaceuticals LLC

Approved

9 2

Actigall

Mitosol

Retin-a

VValeant Pharmaceuticals

Approved

—5

Amoxil

GGlobal Antibiotics Research and Development Partnership

Zocor

1 7

Azulfidine

Pfizer

Phase 2

1 8

Thalomid

Bristol-Myers Squibb

Phase 2

1 9

Iqirvo

Ipsen

Phase 2

1 10

Tricor

JJagotec

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Not yet recruiting

Sclerosing Cholangitis

NCT06886360

Clinical

Trials by Indication[1]

Sclerosing Cholangitis1 trial

Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

Not yet recruiting·—·Phase 3·NCT06886360·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for norucholic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — norucholic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for norucholic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dr. Falk Pharma GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: DDr. Falk Pharma GmbH

norucholic acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Sclerosing Cholangitis1 trial

References

Drug Info

Quick Facts

Related News